Neoplasm by Special Category

Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC)

PMID 23515910 · Zhang et al., 2013 · Open in CIViC

MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor.

PMID 25730903 · Saiki et al., 2015 · Open in CIViC

MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional T… (full text at CIViC)

PMID 17671205 · Efeyan et al., 2007 · Open in CIViC

Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild … (full text at CIViC)

PMID 26459177 · Andreeff et al., 2016 · Open in CIViC

TP53 Y220C is known to destabilize p53 and down-regulate p53-mediated apoptosis. The success of bortezomib may be explained by the previously reported up-regulation of caspase-mediated apoptosis, whic… (full text at CIViC)

PMID 28679691 · Meißner et al., 2017 · Open in CIViC

A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC)

PMID 11595686 · Reles et al., 2001 · Open in CIViC

56-year-old women was diagnosed with a stage IV ovarian cancer. Debulking surgery, and chemotherapy was given for 10 months. However, disease recurred and at this time NGS was performed which detected… (full text at CIViC)

PMID 35251641 · Endo et al., 2022 · Open in CIViC

In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

A male child (1 year old) presented with a rapidly growing tumor in the cervical region that had been present for 2 months. It was a firm to hard soft-tissue mass. Radiologic imaging disclosed a tumor… (full text at CIViC)

PMID 32489127 · Rekhi et al., 2021 · Open in CIViC

In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

TPT1(TCTP) overexpression was detected in several tumour types and silencing of TPT1 was shown to induce tumour reversion. There is a reciprocal repression between TPT1 and P53. Sertraline interacts w… (full text at CIViC)

PMID 28751755 · Boia-Ferreira et al., 2017 · Open in CIViC

A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was "pan-negative" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was foun… (full text at CIViC)

PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC

Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression o… (full text at CIViC)

PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC

In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas… (full text at CIViC)

PMID 29683819 · Lezcano et al., 2018 · Open in CIViC

In a molecular analysis comparing 46 apocrine cutaneous mixed tumors (CMTs) with 45 salivary gland pleomorphic adenomas (PAs), TRPS1::PLAG1 was the predominant PLAG1 fusion in CMTs and was significant… (full text at CIViC)

PMID 39468990 · Alsugair et al., 2024 · Open in CIViC

This study describes two novel PLAG1 fusions, TRPS1–PLAG1 and NDRG1–PLAG1, identified in histologically confirmed cases of chondroid syringoma. Both fusions involve promoter swapping, placing PLAG1 ex… (full text at CIViC)

PMID 32345665 · Panagopoulos et al., 2020 · Open in CIViC

A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 … (full text at CIViC)

PMID 22923433 · Iyer et al., 2012 · Open in CIViC

Tumors (n=14) expressing TSC1 mutations (5/14) show notably more sensitivity to everolimus than their wild-type counterparts (9/14). A dramatic response was observed in a patient with combination of L… (full text at CIViC)

PMID 22923433 · Iyer et al., 2012 · Open in CIViC

In a retrospective study of 79 RCC patients treated with diverse rapalogs (mTOR inhibitors) inactivating TSC1 and TSC2-mutations and activating MTOR-mutations were significantly more common in respons… (full text at CIViC)

PMID 26831717 · Kwiatkowski et al., 2016 · Open in CIViC

In a retrospective study of 79 RCC patients treated with diverse rapalogs (mTOR inhibitors) inactivating TSC1 and TSC2-mutations and activating MTOR-mutations were significantly more common in respons… (full text at CIViC)

PMID 26831717 · Kwiatkowski et al., 2016 · Open in CIViC

In a phase II trial of everolimus in thyroid cancer (NCT00936858), seven patients with anaplastic thyroid carcinoma were treated, and only one patient achieved an objective response. This 57-year-old … (full text at CIViC)

PMID 25295501 · Wagle et al., 2014 · Open in CIViC

Prostate cancer cell lines over-expressing TSPYL1 P62S had similar levels of cell proliferation as control cells normally expressing TSPYL1 wildtype when treated with abiraterone. Authors note that TS… (full text at CIViC)

PMID 29027195 · Qin et al., 2018 · Open in CIViC

In a prospective clinical trial, 87 metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone acetate/prednisone (AA/P) showed that TSPYL1 R62S (NC_000006.11:g.11660081… (full text at CIViC)

PMID 29027195 · Qin et al., 2018 · Open in CIViC

6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.

PMID 19040416 · Barletta et al., 2009 · Open in CIViC

High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines.

PMID 21576762 · Ganguly et al., 2011 · Open in CIViC

High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.

PMID 23218766 · Wang et al., 2013 · Open in CIViC

TYK2 protein overexpression was observed in 60% of MPNST cases using an independently generated tissue microarray, regardless of NF1 status. A total of 3 women and 4 men with NF1-MPNST were studied (m… (full text at CIViC)

PMID 27875628 · Hirbe et al., 2017 · Open in CIViC

In this 2020 study, the authors analyzed bone marrow samples from 62 B-ALL patients at diagnosis using next-generation sequencing (NGS) to search for disease-associated TYK2 gene variants. The patient… (full text at CIViC)

PMID 33260630 · Turrubiartes-Martínez et al., 2020 · Open in CIViC

The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with i… (full text at CIViC)

PMID 20628391 · Martinez-Balibrea et al., 2010 · Open in CIViC

Genomic DNA from liver metastases of four different colorectal cancer patients who had previously undergone 5-FU-based adjuvant chemotherapy was evaluated using digital karyotyping. TYMS amplification… (full text at CIViC)

PMID 14970324 · Wang et al., 2004 · Open in CIViC

The TYMS DNA copy number was analyzed in 111 patient samples, divided into two groups: those exposed to 5-FU (n = 62) and those not exposed to 5-FU (n = 49). It was found that the 5-FU exposed group h… (full text at CIViC)

PMID 20727737 · Watson et al., 2010 · Open in CIViC